CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio’s proprietary 10B10 antibody.
CrownBio will present data on its latest scientific developments including the impact of intestinal microbiota on anti-PD-L1 immunotherapy, the development of primary tumor allograft models for pre...
CrownBio’s clients will now be able to purchase hundreds of products on-line across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immu...
OncoExpress has also become available as a mobile app for both Apple and Android operating systems to enable users to access high level model data from their mobile devices “on-the-go”.
CrownBio has expanded its CVMD services capacity by investing in facilities at the University of Louisiana at Lafayette’s New Iberia Research Center (NIRC), the largest national primate research ce...
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics dev...
MuBase offers a user-friendly experience while searching a large collection of model data, including tumor pathology, genomic characterization, and in vivo pharmacology data with standard of care a...
CrownBio’s models are unparalleled in their translatability and enable clinically translatable evaluation of therapeutics that target not only kidney complications, but also hyperglycemia in diabet...
18 of 24
Receive JSR Life Sciences news on your RSS reader.
